Cargando…
Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer
Endometrial cancer is common, and a subset recurs and requires additional treatment. Some of these are recognized as being susceptible to immune therapies and are said to have mismatch repair deficiency (dMMR). However, this clinical trial highlights which cases are more likely to respond well: thos...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300166/ https://www.ncbi.nlm.nih.gov/pubmed/34875102 http://dx.doi.org/10.1002/cncr.34024 |